Bruker Corp
BRKR
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
73.7% downsideOvervalued by 73.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.96 Billion |
|---|---|
| Enterprise Value | $10.98 Billion |
| Dividend Yield | $0.20 (0.34%) |
| Earnings per Share | $-0.15 |
| Beta | 1.12 |
| Outstanding Shares | 152,200,000 |
Return
| Return on Equity | -0.47% |
|---|---|
| Return on Assets | -0.19% |
| Return on Invested Capital | 0.81% |
Valuation & Multiples
| P/E Ratio | -772.68 |
|---|---|
| PEG | 4481.53 |
| Price to Sales | 2.73 |
| Price to Book Ratio | 3.75 |
| Enterprise Value to Revenue | 3.18 |
| Enterprise Value to EBIT | 285.25 |
| Enterprise Value to Net Income | -947 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.87 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7776▲ 26.64% |
|---|---|
| Total Calls | 216,700▼ 62.33% |
| Total Puts | 168,500▼ 42.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 90.17%▲ 0.81% |
|---|---|
| Total Invested | $4.94B▼ 22.92% |
| Investors Holding | 347▼ 24.00% |
ESG Score
No data
About Bruker Corp
6,000 employees
CEO: Frank Laukien Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scienti c instruments and high-value analytical and diagnostic solutions enable...
Relevant Senate Committees
The most powerful economic committee, controlling taxation and trade. Its decisions on corporate tax policy and international trade directly impact Bruker's profitability and global market operations.
Directly allocates federal spending. Its subcommittees determine precise funding for scientific research, healthcare, and government programs, which are significant for Bruker's sales to academic, government, and clinical customers.
Regulates the FDA and NIH. FDA oversight directly impacts Bruker's diagnostic and clinical solutions, while NIH funding is crucial for life science molecular research, a core market.
Possesses vast jurisdiction over interstate commerce and science. It can influence R&D funding, technology standards, and regulations that directly impact Bruker's scientific instrument and solutions business.